Schering Aktiengesellschaft

Bayer Schering Pharma Ag

Therapharm Gmbh

Klaus Bosslet

Ulrich Klar

Gerhard Siemeister

Markus Berger

Andreas Menrad

Andrea Rotgeri

Jens Hoffmann

Holger Hess-Stumpp

Ivan Benes

Kim Orchard

Ladislav Droz

The present invention relates to the use of radioimmunoconjugates for the treatment of haematological malignancies, particularly multiple myeloma.

Immunoconjugate for human CD66 for the treatment of multiple myeloma and other haematological malignancies

Conjugates of epothilones and epothilone derivatives (as effectors) with suitable saccharides or saccharide derivatives (as recognition units) are described. Their production is carried out by the recognition units being reacted with suitable linkers, and the compounds that are produced are conjugated to the effectors. The pharmaceutical use of the conjugates for treating proliferative or angiogenesis-associated processes is described.

Effector conjugates, methods for their preparation and their pharmaceutical use

Conjugates of epothilones and epothilone derivatives (as effectors) with suitable biomolecules (as recognition units) are described. Their production is carried out by the effectors being reacted with suitable linkers, and the compounds that are produced are conjugated to the recognition units. The pharmaceutical use of the conjugates for treating proliferative or angiogenesis-associated processes is described.

Effector conjugates, process for their production and their pharmaceutical use

Growing community of inventors

Berlin, Germany

Klaus Bosslet